EcoR1 Capital ALLK Position
Exited8-Fund ConvergenceEcoR1 Capital exited their position in Allakos Inc. (ALLK) in Q1 2024, after holding the stock for 4 quarters.
The position was first reported in Q2 2023 and has been tracked across 4 quarterly 13F filings.
ALLK is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Allakos Inc.
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Full company profile →EcoR1 Capital ALLK Position History
Frequently Asked Questions
Does EcoR1 Capital own ALLK?
No. EcoR1 Capital exited their position in Allakos Inc. (ALLK) in Q1 2024. They previously held the stock for 4 quarters.
How many hedge funds own ALLK?
8 specialist biotech hedge funds currently hold ALLK, including BVF Partners, Deep Track Capital, Redmile Group and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did EcoR1 Capital first buy ALLK?
EcoR1 Capital's position in ALLK was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is EcoR1 Capital's ALLK position increasing or decreasing?
EcoR1 Capital completely exited their ALLK position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ALLKCompany Page →
All fund holders, insider trades, catalysts, and cash runway
EcoR1 CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →